Tirzepatide outperforms semaglutide for real-world weight loss

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become massively popular for weight loss, but results vary from person to person and drug to drug. Venky Soundararajan and colleagues explore the full range of responses to tirzepatide (e.g., Mounjaro or Zepbound) and semaglutide (e.g.,Ozempic, Wegovy, or Rybelsus) by analyzing de-identified electronic health records for matched cohorts of 10,339 tirzepatide-treated and 10,339 semaglutide-treated patients.

Source:

PNAS Nexus

Journal reference: